None
Quote | Eidos Therapeutics Inc. (NASDAQ:EIDX)
Last: | $122.21 |
---|---|
Change Percent: | -4.85% |
Open: | $127.57 |
Close: | $122.21 |
High: | $128.49 |
Low: | $116.83 |
Volume: | 334,481 |
Last Trade Date Time: | 01/25/2021 04:55:48 pm |
News | Eidos Therapeutics Inc. (NASDAQ:EIDX)
Citi analyst Joel Beatty has downgraded shares of Alnylam (ALNY) from buy/high risk to neutral/high risk amid upside threats.Beatty, however, increased his price target $5 to $175.He cities competitor threats to Alnylam's hereditary ATTR (amyloidosis) business from Eidos Therapeutics' (EIDX) ...
BridgeBio Pharma (BBIO) announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics (EIDX).BridgeBio agreed to acquire all of the outstanding common stock of Eidos it did not already own, representing ~36.3% of outstanding shares, in Octobe...
Message Board Posts | Eidos Therapeutics Inc. (NASDAQ:EIDX)
Subject | By | Source | When |
---|---|---|---|
Just In: $EIDX SHAREHOLDER NOTICE: Brodsky & Smith, | whytestocks | investorshub | 10/05/2020 11:15:22 PM |
NEWS: $EIDX Why Eidos Therapeutics Stock Is Skyrocketing Today | whytestocks | investorshub | 10/05/2020 6:30:43 PM |
News; $EIDX ($EIDX) Alert: Johnson Fistel Investigates Proposed | whytestocks | investorshub | 10/05/2020 6:15:33 PM |
News: $EIDX CORRECTION: BridgeBio and Eidos Present Data | whytestocks | investorshub | 11/17/2019 12:15:19 AM |
News: $EIDX BridgeBio and Eidos Present Data from | whytestocks | investorshub | 11/16/2019 11:00:27 PM |
News, Short Squeeze, Breakout and More Instantly...
Eidos Therapeutics Inc. Company Name:
EIDX Stock Symbol:
NASDAQ Market:
Eidos Therapeutics Inc. Website:
PALO ALTO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. (“Eidos”) (formerly Nasdaq: EIDX) common st...
PALO ALTO, Calif. and SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced that the stockholders of each of BridgeBio and Eidos voted to approve ...
PALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today that the acquisition of shares of common stock of Eidos not held by Br...